BMJ 2002;325:1202 ( 23 November )

Papers

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

David S Wald, specialist registrar in cardiology a, Malcolm Law, professor b, Joan K Morris, senior lecturer b. 

a Department of Cardiology, Southampton General Hospital, Southampton SO16 6YD, b Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, London EC1M 6BQ

Correspondence to D S Wald davidwald{at}hotmail.com


    Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References

Objective: To assess whether the association of serum homocysteine concentration with ischaemic heart disease, deep vein thrombosis and pulmonary embolism, and stroke is causal and, if so, to quantify the effect of homocysteine reduction in preventing them.
Design: Meta-analyses of the above three diseases using (a) 72 studies in which the prevalence of a mutation in the MTHFR gene (which increases homocysteine) was determined in cases (n=16 849) and controls, and (b) 20 prospective studies (3820 participants) of serum homocysteine and disease risk.
Main outcome measures: Odds ratios of the three diseases for a 5 µmol/l increase in serum homocysteine concentration.
Results: There were significant associations between homocysteine and the three diseases. The odds ratios for a 5 µmol/l increase in serum homocysteine were, for ischaemic heart disease, 1.42 (95% confidence interval 1.11 to 1.84) in the genetic studies and 1.32 (1.19 to 1.45) in the prospective studies; for deep vein thrombosis with or without pulmonary embolism, 1.60 (1.15 to 2.22) in the genetic studies (there were no prospective studies); and, for stroke, 1.65 (0.66 to 4.13) in the genetic studies and 1.59 (1.29 to 1.96) in the prospective studies.
Conclusions: The genetic studies and the prospective studies do not share the same potential sources of error, but both yield similar highly significant results---strong evidence that the association between homocysteine and cardiovascular disease is causal. On this basis, lowering homocysteine concentrations by 3 µmol/l from current levels (achievable by increasing folic acid intake) would reduce the risk of ischaemic heart disease by 16% (11% to 20%), deep vein thrombosis by 25% (8% to 38%), and stroke by 24% (15% to 33%).

What is already known on this topic
There is an association between serum homocysteine concentration and cardiovascular disease, but it is not known whether the association is causal

A common single gene mutation that reduces the activity of an enzyme involved in folate metabolism (MTHFR) is associated with a moderate (20%) increase in serum homocysteine

What this study adds
A meta-analysis of MTHFR studies shows a significantly higher risk of both ischaemic heart disease and deep vein thrombosis (with or without pulmonary embolism) in people with the MTHFR mutation

A meta-analysis of prospective studies shows a significant association between homocysteine concentration and ischaemic heart disease similar in size to that expected from the results of the MTHFR studies and a significant association with stroke

The MTHFR studies and the prospective studies do not share the same potential sources of error but both yield similar results---strong evidence that the association between homocysteine and cardiovascular disease is causal

On this basis a decrease in serum homocysteine of 3 µmol/l (achievable by daily intake of about 0.8 mg folic acid) should reduce the risk of ischaemic heart disease by 16%, deep vein thrombosis by 25%, and stroke by 24%




    Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References

The serum concentration of the amino acid homocysteine is positively associated with the risk of ischaemic heart disease, deep vein thrombosis and pulmonary embolism, and stroke. 1 2 There is uncertainty over whether these associations are causal. 3 4 Resolving the question of causality is important because serum homocysteine can be lowered by the B vitamin folic acid, 5 6 raising the prospect of a simple and safe means of prevention.

Three rare autosomal recessive disorders (the homocystinurias), in which homozygotes lack one of the three principal enzymes in homocysteine metabolism, cause extremely high serum homocysteine levels (>100 µmol/l) and a high risk of premature cardiovascular disease (affecting half of homozygotes by the age of 307). The biochemical change that is common to all three disorders is a high serum homocysteine concentration (no other substance is consistently high or low), 8 9 indicating that high homocysteine levels cause cardiovascular disease.

Whether moderate increases in serum homocysteine cause cardiovascular disease has been the subject of debate. Moderate increases occur as a result of a mutation in the gene coding for the enzyme methylenetetrahydrofolate reductase (MTHFR) in which cytosine is replaced by thymidine (Cright-arrowT) at base position 677 of the gene. This variant of the enzyme has reduced activity,10 resulting in an elevation of serum homocysteine concentrations of about 20%.11 The presence of the mutation offers a natural experiment in which the population have, in effect, been randomly allocated to one group with higher homocysteine concentrations or one with a lower level. There is no reason to expect that the two groups differ in any systematic way other than in their serum homocysteine. The Cright-arrowT mutation is surprisingly common, with about 10% of people in the population being homozygous affected (TT), 47% homozygous unaffected (CC), and 43% heterozygotes (CT). However, because the increase in homocysteine is relatively small and the impact of the mutation varies according to the folate intake in the population, studies comparing the risk of cardiovascular disease in people with and without the TT mutation need large numbers to be able to show an effect if one were present. Previous meta-analyses have had too few studies available to do this.11-13

We present a new meta-analysis of the MTHFR studies (including data from an additional 34 studies since the previous meta-analyses), which has the statistical power to show an effect. We compare these results with those of a meta-analysis of prospective studies of serum homocysteine and disease events. We assess the evidence for causality between serum homocysteine and ischaemic heart disease, deep vein thrombosis with or without pulmonary embolism, and stroke and estimate the size of the associations with the three diseases.


    Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References

Identification of studies
We sought two types of study on the association between serum homocysteine and ischaemic heart disease, deep vein thrombosis, or stroke:

  • Studies reporting the prevalence of the genetic variant of the MTHFR enzyme (homozygous (TT) and heterozygous (CT) compared with "wild type" (CC)) in cardiovascular disease cases and controls.w1-w94 Some of these studies also reported the associated differences in serum homocysteine
  • Prospective (cohort) studies of serum homocysteine and disease events.w95-w120 Serum was collected at baseline, and homocysteine concentration measured either then on all subjects or later on stored samples from those who subsequently developed disease events and from matched controls (nested case-control design).

To identify studies, we searched databases (Medline, CINAHL, Embase, the Cochrane Library, PsycINFO, and ClinPSYC) in any language up to October 2001. Subject headings were homocysteine, homocystine, methylenetetrahydrofolate reductase or MTHFR and ischaemic heart disease, coronary artery disease, myocardial infarction, cerebrovascular disease, stroke, deep vein thrombosis, pulmonary embolism, or thromboembolic disease. We included studies that measured fasting or non-fasting serum or plasma homocysteine concentration using any standard laboratory method but excluded studies reporting only homocysteine measured after methionine loading. We excluded studies of children (aged <18 years) and of haemodialysis or renal transplant patients. In the MTHFR studies we restricted our analysis to studies in which the genetic variant was confirmed by DNA testing.

The primary search generated 171 potentially relevant articles, of which 96 met the above criteria. We also scanned the citations lists of these 96 studies and of review articles, yielding 24 extra studies to make 120 studies in total.

Definition of outcomes
In the MTHFR studies patients with ischaemic heart disease had myocardial infarction or angiographically confirmed coronary artery occlusion (>50% of the luminal diameter). Cases of deep vein thrombosis cases included patients with or without pulmonary embolism. Stroke cases were cerebral infarction or cerebral haemorrhage identified either clinically or by computed tomography or magnetic resonance imaging. The control groups were from the general population, except for some ischaemic heart disease studies, when they were patients who underwent coronary angiography with normal coronary arteries. In cohort studies the end points were death from ischaemic heart disease or non-fatal myocardial infarction, or fatal stroke or non-fatal cerebral infarction or haemorrhage. Data for analysis were extracted independently by two of the authors, and the data sets cross checked.

Statistical methods
For each MTHFR study we determined the odds ratio of being homozygous (TT), and in a separate analysis heterozygous (CT), for the mutant allele compared with being homozygous for the wild type allele (CC) in cases and controls.

In the prospective studies we estimated odds ratios for a 5 µmol/l increase in serum homocysteine (a standard reference increment). In studies that did not report this directly we estimated it as follows. In studies reporting an odds ratio for a specified proportional difference in serum homocysteine we took the homocysteine values 2.5 µmol/l above and below the study mean and, from the proportional difference between these two values, calculated the odds ratio corresponding to this 5 µmol/l difference in homocysteine. In studies reporting odds ratios in subgroups defined by ranked homocysteine concentration we fitted a logistic regression line to the data.

We used a random effects model to derive summary odds ratios from combinations of studies to allow for any heterogeneity across studies. In the prospective studies we adjusted the summary odds ratios for regression dilution bias14; these arose because the serum homocysteine values in each person were from single measurements, which are unrepresentative of a person's long term average value over the period of follow up. We corrected for regression dilution bias by raising the summary odds ratio to the power of the ratio of total (between-person plus within-person) variance to between-person variance. With serum homocysteine this ratio increases over time15 (in addition to random short term fluctuations in serum homocysteine within a person6 there may be longer term variations from a variable rate of increase in homocysteine with age). We used a published estimate of 1.33 for the correction factor in the prospective studies (5 year average interval between blood collection and cardiovascular disease events).15




    Results
Top
Abstract
Introduction
Methods
Results
Discussion
References

Ischaemic heart disease

Studies of MTHFR mutation
Fig 1 shows the results of the 46 MTHFR studies of ischaemic heart disease (12 193 cases in total, mean age at time of event 55 years). The odds ratios of homozygotes for the mutant allele (TT) compared with wild type homozygotes (CC) are shown, with the studies ranked in order of increasing effect. There was a wide range of estimates, but the summary odds ratio was 1.21 (95% confidence interval 1.06 to 1.39; P=0.006), indicating that risk was on average 21% higher in TT homozygotes than in CC homozygotes. The summary odds ratio for the heterozygous state (CT v CC) was 1.06 (0.99 to 1.13; P=0.09).



View larger version (33K):
[in this window]
[in a new window]
  		Fig 1.   Results of published studies of association between MTHFR mutation and ischaemic heart disease: values are odds ratios (95% confidence intervals) for homozygotes for mutant allele (TT) v wild type (CC)

From the 33 studies that provided relevant data, the mean difference in serum homocysteine concentration between the TT and CC genotypes was 2.7 µmol/l (2.1 to 3.4 µmol/l) and that between the CT and CC genotypes was 0.29 µmol/l (0.20 to 0.39 µmol/l) (table 1). The summary odds ratio of 1.21 for TT v CC is equivalent to an odds ratio of 1.42 (1.11 to 1.84) for the standard 5 µmol/l increase in serum homocysteine (calculated by raising 1.21 to the power of 5/2.7).


                              
View this table:
[in this window]
[in a new window]
 

Table 1.  Studies reporting serum homocysteine concentrations (µmol/l) according to MTHFR genotype (homozygotes for the mutant allele (TT), heterozygotes (CT), and wild type homozygotes (CC))

Combining the results from 12 of the MTHFR studies in which other cardiovascular risk factors were measuredw7 w9 w19 w20 w37 w38 w42 w46 w86 w89 w93 w94 showed that TT and CC homozygotes had similar serum cholesterol concentration, blood pressure, smoking prevalence, and body mass index, with no significant differences. The upper confidence intervals of these risk factors' associations with TT homozygotes were 0.02 mmol/l, 3 mm Hg, 6%, and 0.9 kg/m2 higher respectively; applying these to the quantitative association of each risk factor with ischaemic heart disease16 showed that even if there were confounding by another risk factor it could at most account for half the 21% excess risk seen in TT homozygotes.

Prospective studies and cardiovascular disease
Fig 2 (upper part) shows the results of 16 prospective studies on ischaemic heart disease (3144 events, mean age at event 62 years).w95-w120 The odds ratios are adjusted for age, sex, smoking, blood pressure, and serum cholesterol concentration in all the studies except one, which is adjusted for age and sex only.w106 The summary odds ratio was 1.23 (1.14 to 1.32) for a 5 µmol/l increase in serum homocysteine concentration, or 1.32 (1.19 to 1.45) adjusted for regression dilution bias. There was a suggestion of a trend across the prospective studies for a decreasing odds ratio with increasing age at the time of the event (P=0.07), as has been observed for other cardiovascular risk factors (smoking, serum cholesterol, and blood pressure).



View larger version (32K):
[in this window]
[in a new window]
  		Fig 2.   Results of prospective studies of serum homocysteine concentration and ischaemic heart disease and stroke: values are odds ratios (95% confidence intervals) for a 5 µmol/l increase in serum homocysteine, adjusted for age, sex, smoking, cholesterol concentration, and blood pressure (except in one study, adjusted for age and sex alonew106) but not for regression dilution bias

Deep vein thrombosis
Fig 3 shows the results of the 26 MTHFR studies of deep vein thrombosis (3439 cases, mean age at event 44 years). The summary odds ratio for homozygotes for the mutant allele (TT) compared with wild type homozygotes (CC) was 1.29 (1.08 to 1.54; P=0.007), equivalent to an odds ratio of 1.60 (1.15 to 2.22) for a 5 µmol/l increase in serum homocysteine concentration. The summary odds ratio associated with the heterozygous state (CT v CC) was 1.05 (0.94 to 1.19; P=0.41).



View larger version (29K):
[in this window]
[in a new window]
  		Fig 3.   Results of published studies of association between the MTHFR mutation and deep vein thrombosis: values are odds ratios (95% confidence intervals) for homozygotes for mutant allele (TT) v wild type (CC)

There were no published prospective studies.

Stroke
The seven MTHFR studies of stroke (1217 cases, mean age at event 63 years) yielded relatively few data, so the confidence interval for the summary result was wide: the odds ratio for homozygotes for the mutation (TT) compared with wild type homozygotes was 1.31 (0.80 to 2.15), equivalent to an odds ratio of 1.65 (0.66 to 4.13) for a 5 µmol/l increase in serum homocysteine. The summary odds ratio associated with the heterozygous state (CT v CC) was 1.15 (0.93 to 1.42).

Fig 2 (lower part) shows the results of the eight prospective studies (676 events, mean age at event 70). The results are adjusted for age, sex, smoking, blood pressure, and serum cholesterol in all the studies. The summary odds ratio for a serum homocysteine increase of 5 µmol/l was 1.42 (1.21 to 1.66), or 1.59 (1.29 to 1.96) adjusted for regression dilution bias.

Studies excluded
Four prospective studies could not be included in the analysis. Two reported only on all cardiovascular diseases in combination; these both showed positive associations between homocysteine concentration and mixed vascular disease.w118 w119 Two studies reported odds ratios only relative to a specified homocysteine cut-off value.w92 w116 We could not accurately calculate an odds ratio for a 5 µmol/l increase in homocysteine from this, but estimating a value for these two studies and including them in the analysis had negligible effect (the odds ratio for ischaemic heart disease did not change, that for stroke changed from 1.59 to 1.56).




    Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References

The MTHFR studies show highly significant associations between serum homocysteine concentration and ischaemic heart disease and deep vein thrombosis. Previous meta-analyses of the MTHFR studies failed to show an effect because they lacked statistical power, but their confidence intervals were consistent with the significant estimates we present here. 11-13 17 Our analyses combine data from an extra 23 studies on ischaemic heart disease and an extra 11 studies on deep vein thrombosis since the largest previous meta-analyses. 12 17

The MTHFR studies on ischaemic heart disease and stroke showed significant heterogeneity (greater variation between study results than would be expected through chance). This is not surprising since the expression of the mutation is likely to depend on environmental factors, particularly dietary folate,11 which reduces homocysteine levels. Thus, in MTHFR studies carried out in areas where folate intake is low one would expect to find a larger difference between TT and CC homozygotes in rates of heart disease but also a larger difference in homocysteine concentrations. Heterogeneity, therefore, should not invalidate the analysis provided the results are expressed in terms of the associated differences in homocysteine concentrations.

The prospective studies show a highly significant association between serum homocysteine concentration and both ischaemic heart disease and stroke. The absence of significant heterogeneity across the 16 studies (P=0.12) does not support the view 3 4 9 that these studies divide into two groups, one with clearly positive results and one with clearly negative results (this can also be seen in fig 2).

Interpretation of evidence for causality
The results of the MTHFR and the prospective studies can be explained in one of two ways---a direct (or causal) explanation or an indirect (non-causal) explanation. An indirect explanation would depend on the MTHFR and prospective studies both showing associations with homocysteine through confounding. In the MTHFR studies the difference in homocysteine concentration arises from a single gene mutation effectively allocated at random. There is therefore no basis for expecting that people with the mutant gene would systematically differ from those without it in other cardiovascular risk factors (smoking, blood pressure, serum cholesterol concentration), and the data show that they do not. Genetic confounding is theoretically possible, whereby a gene linked to the MTHFR gene controls some unknown risk factor and coincidentally increases serum homocysteine concentration.

In the prospective studies confounding from smoking, blood pressure, and serum cholesterol was allowed for; if there were any remaining confounding it would also be from an unknown factor associated with both serum homocysteine and cardiovascular disease. Importantly, the genetic linkage that one would have to postulate to explain the association with cardiovascular disease in the MTHFR studies could not account for the association in the prospective studies---because the increase in risk of about a quarter with the MTHFR variant is so much smaller than the twofold difference in risk (10th to 90th centile) in the prospective studies. The indirect explanation relies on a complex and improbable series of different associations that coincidentally yield similar cardiovascular disease risks for a given difference in serum homocysteine concentration. The direct (causal) explanation is plausible and much simpler.

Substantial publication bias is unlikely because many of the individual study results were not statistically significant (those in which the confidence intervals cross 1.0 in figs 1 and 3), and many of these were interpreted by their authors as being negative. A standard statistical assessment of publication bias (the regression asymmetry test18) showed no basis for concern in either the ischaemic heart disease studies (P=0.55) or the deep vein thrombosis studies (P=0.43).

Evidence of risk reduction
A placebo controlled randomised trial of treatment with B vitamins (folic acid, B-6, and B-12) to lower serum homocysteine concentration in patients with ischaemic heart disease has shown a rapid reduction of risk.19 There were 13 major cardiac events (coronary death, non-fatal myocardial infarction, or revascularisation procedure) over six months in 102 vitamin treated patients and 23 events in 94 placebo treated patients (P=0.04).19 Studies of patients with homocystinuria treated with B vitamins have also shown reduction in risk. In one study treatment with B vitamin led to two vascular events when 30 would have been expected (from previous observation in untreated patients), and in another study there were two events when 21 would have been expected. 7 20


                              
View this table:
[in this window]
[in a new window]
 

Table 2.  Summary results from the MTHFR studies and the prospective studies on risk of ischaemic heart disease, deep vein thrombosis with or without pulmonary embolism, and stroke associated with serum homocysteine concentration

Table 2 summarises the odds ratios of ischaemic heart disease, deep vein thrombosis, and stroke for the standard 5 µmol/l increase in homocysteine concentration and shows combined odds ratios from the two types of study. For ischaemic heart disease this was 1.33 (95% confidence interval 1.22 to 1.46), and for stroke it was 1.59 (1.30 to 1.95). Table 2 also converts the odds ratios for a 5 µmol/l increase in homocysteine concentration into odds ratios for a 3 µmol/l decrease in homocysteine (the maximal effect of folic acid, achieved with a daily dose of about 0.8 mg). 5 6 On the basis that the association is causal and reversible, we estimate that folic acid could reduce the risk of ischaemic heart disease by 16%, deep vein thrombosis by 25%, and stroke by 24%. The folic acid could be taken as tablets by high risk patients, and possibly supplied to the general public through food fortification or a combination of both.

Conclusion
Our results strengthen the evidence that a raised serum homocysteine concentration is a cause of cardiovascular disease. Our conclusion that it is a cause rests on the following observations:

  • The genetic (MTHFR) studies show a moderate increase in risk for a moderate increase in serum homocysteine; genetic linkage to some unknown risk factor might be the explanation although no such linkage is known
  • The prospective studies show an association between serum homocysteine and cardiovascular disease after allowance for confounding
  • These two types of study are susceptible to different sources of error but show quantitatively similar associations, a result that is unlikely to have occurred through different potential sources of confounding acting independently
  • The homocystinurias cause high serum homocysteine levels and high risks of premature cardiovascular disease
  • Lowering serum homocysteine reduced risk, both in a randomised trial in patients with heart disease and in patients with homocystinuria.

In the light of these five observations we could not have concluded otherwise.



    Acknowledgments

We thank Nicholas Wald for his suggestions throughout this project and for his comments on the manuscript. DSW also holds an honorary research fellowship at the Wolfson Institute of Preventive Medicine, St Bartholomew's and the Royal London School of Medicine and Dentistry. At the time of our checking the proofs of our paper, two other meta-analyses were published in relation to ischaemic heart disease and stroke, yielding results consistent with our own. 21 22

Contributors: DW, ML and JM were involved in the analysis and interpretation of the data and in writing the manuscript. DW is guarantor for the study.

    Footnotes

Funding: None.

Competing interests: None declared.

The references used in the meta-analysis appear on bmj.com


    References
Top
Abstract
Introduction
Methods
Results
Discussion
References

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057[Abstract/Free Full Text].
2. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease. Systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-292[Medline].
3. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999; 131: 363-375[Abstract/Free Full Text].
4. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. J Am Coll Cardiol 2000; 86: 1005-1009.
5. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-898[Abstract/Free Full Text].
6. Wald DS, Bishop L, Wald NJ, Law MR, Hennessy E, McPartlin J, et al. Randomised trial of folic acid supplementation on serum homocysteine levels. Arch Intern Med 2001; 161: 695-700[Abstract/Free Full Text].
7. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta -synthase deficiency. Am J Hum Genet 1997; 37: 1-31.
8. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20: 295-300[CrossRef][Web of Science][Medline].
9. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischaemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-867[Abstract/Free Full Text].
10. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofoloate reductase. Nat Genet 1995; 10: 111-113[CrossRef][Web of Science][Medline].
11. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998; 98: 2520-2526[Abstract/Free Full Text].
12. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GH, Heil SG, Bruschke AV, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-2577[Abstract/Free Full Text].
13. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrogolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 2000; 153: 161-168[CrossRef][Web of Science][Medline].
14. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774[CrossRef][Web of Science][Medline].
15. Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001; 8: 363-369[CrossRef][Web of Science][Medline].
16. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570-1576[Free Full Text].
17. Brattstrom L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315-323[Abstract/Free Full Text].
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634[Abstract/Free Full Text].
19. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600[Abstract/Free Full Text].
20. Kluijtmans LAJ, Boers GHD, Kraus JP, van den Henvel LPWJ, Cruysberg JRM, Trijbels FJM, et al. The molecular basis of cystathionine beta -synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Gen 1999; 65: 59-67[CrossRef][Web of Science][Medline].
21. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten FG, et al. MTHFR 677Cright-arrowT polymorphism and risk of coronary heart disease. JAMA 2002; 288: 2023-2031[Abstract/Free Full Text].
22. Homocysteine Studies Collaboration. Homocysteine and risk of ischaemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015-2022[Abstract/Free Full Text].

(Accepted 12 August 2002)

© BMJ 2002
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study
Wouter de Ruijter, Rudi G J Westendorp, Willem J J Assendelft, Wendy P J den Elzen, Anton J M de Craen, Saskia le Cessie, and Jacobijn Gussekloo
BMJ 2009 338: a3083. [Abstract] [Full Text] [PDF]

Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
David S Wald, Nicholas J Wald, Joan K Morris, and Malcolm Law
BMJ 2006 333: 1114-1117. [Full Text] [PDF]

Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?
Sarah J Lewis, Shah Ebrahim, and George Davey Smith
BMJ 2005 331: 1053. [Abstract] [Full Text] [PDF]

The polypill and cardiovascular disease
Tom Fahey, Peter Brindle, and Shah Ebrahim
BMJ 2005 330: 1035-1036. [Extract] [Full Text] [PDF]

What can mendelian randomisation tell us about modifiable behavioural and environmental exposures?
George Davey Smith and Shah Ebrahim
BMJ 2005 330: 1076-1079. [Extract] [Full Text] [PDF]

Folate and risk of cardiovascular disease
David S Wald, Malcolm Law, Joan Morris, Nicholas J Wald, Joseph Hung, John P Beilby, Matthew W Knuiman, and Mark Divitini
BMJ 2003 326: 1035. [Extract] [Full Text]

High homocysteine causes cardiovascular disease
BMJ 2002 325: 0. [Full Text]

This article has been cited by other articles:

  • Chellappa, P., Ramaraj, R. (2009). Depression, Homocysteine Concentration, and Cardiovascular Events. JAMA 301: 1541-1542 [Full text]  
  • Li, S., Arning, E., Liu, C., Vitvitsky, V., Hernandez, C., Banerjee, R., Bottiglieri, T., Lin, J. D. (2009). Regulation of homocysteine homeostasis through the transcriptional coactivator PGC-1{alpha}. Am. J. Physiol. Endocrinol. Metab. 296: E543-E548 [Abstract] [Full text]  
  • Christen, W. G., Glynn, R. J., Chew, E. Y., Albert, C. M., Manson, J. E. (2009). Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women: The Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 169: 335-341 [Abstract] [Full text]  
  • Kerr, M. A., Livingstone, B., Bates, C. J., Bradbury, I., Scott, J. M., Ward, M., Pentieva, K., Mansoor, M. A., McNulty, H. (2009). Folate, Related B Vitamins, and Homocysteine in Childhood and Adolescence: Potential Implications for Disease Risk in Later Life. Pediatrics 123: 627-635 [Abstract] [Full text]  
  • Hyder, J. A., Allison, M. A., Wong, N., Papa, A., Lang, T. F., Sirlin, C., Gapstur, S. M., Ouyang, P., Carr, J. J., Criqui, M. H. (2009). Association of Coronary Artery and Aortic Calcium With Lumbar Bone Density: The MESA Abdominal Aortic Calcium Study. Am J Epidemiol 169: 186-194 [Abstract] [Full text]  
  • de Ruijter, W., Westendorp, R. G J, Assendelft, W. J J, den Elzen, W. P J, de Craen, A. J M, le Cessie, S., Gussekloo, J. (2009). Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338: a3083-a3083 [Abstract] [Full text]  
  • Antoniades, C., Antonopoulos, A. S., Tousoulis, D., Marinou, K., Stefanadis, C. (2009). Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 30: 6-15 [Abstract] [Full text]  
  • Nenseter, M. S., Ueland, T., Retterstol, K., Strom, E., Morkrid, L., Landaas, S., Ose, L., Aukrust, P., Holven, K. B. (2009). Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects: Effect of Treatment With B-Vitamins. Stroke 40: 241-247 [Abstract] [Full text]  
  • Tsai, M. Y., Loria, C. M., Cao, J., Kim, Y., Siscovick, D., Schreiner, P. J., Hanson, N. Q. (2009). Clinical Utility of Genotyping the 677C>T Variant of Methylenetetrahydrofolate Reductase in Humans Is Decreased in the Post-Folic Acid Fortification Era. J. Nutr. 139: 33-37 [Abstract] [Full text]  
  • Siekmeier, R., Grammer, T., Marz, W. (2008). Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function. J CARDIOVASC PHARMACOL THER 13: 279-297 [Abstract]  
  • Chan, M. Y., Andreotti, F., Becker, R. C. (2008). Hypercoagulable States in Cardiovascular Disease. Circulation 118: 2286-2297 [Full text]  
  • Held, C., Sumner, G., Sheridan, P., McQueen, M., Smith, S., Dagenais, G., Yusuf, S., Lonn, E. (2008). Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med 13: 245-253 [Abstract]  
  • Holven, K. B., Aukrust, P., Retterstol, K., Otterdal, K., Bjerkeli, V., Ose, L., Nenseter, M. S., Halvorsen, B. (2008). The Antiatherogenic Function of HDL Is Impaired in Hyperhomocysteinemic Subjects. J. Nutr. 138: 2070-2075 [Abstract] [Full text]  
  • Borrione, P, Rizzo, M, Spaccamiglio, A, Salvo, R A, Dovio, A, Termine, A, Parisi, A, Fagnani, F, Angeli, A, Pigozzi, F (2008). Sport-related hyperhomocysteinaemia: a putative marker of muscular demand to be noted for cardiovascular risk. Br. J. Sports. Med. 42: 894-900 [Abstract] [Full text]  
  • Milani, R. V., Lavie, C. J. (2008). Homocysteine: The Rubik's Cube of Cardiovascular Risk Factors. Mayo Clin Proc. 83: 1200-1202 [Full text]  
  • Humphrey, L. L., Fu, R., Rogers, K., Freeman, M., Helfand, M. (2008). Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis. Mayo Clin Proc. 83: 1203-1212 [Abstract] [Full text]  
  • Khan, U., Crossley, C., Kalra, L., Rudd, A., Wolfe, C. D.A., Collinson, P., Markus, H. S. (2008). Homocysteine and Its Relationship to Stroke Subtypes in a UK Black Population: The South London Ethnicity and Stroke Study. Stroke 39: 2943-2949 [Abstract] [Full text]  
  • Sadhahalli, P., Myles, P. S., Chan, M., Leslie, K., Peyton, P., Paech, M., Forbes, A. (2008). Folate for high-risk surgical patients. Br J Anaesth 101: 576-576 [Full text]  
  • Dowd, J. B., Aiello, A. E (2008). Did national folic acid fortification reduce socioeconomic and racial disparities in folate status in the US?. Int J Epidemiol 37: 1059-1066 [Abstract] [Full text]  
  • Schwartzfarb, E. M., Romanelli, P. (2008). Hyperhomocysteinemia and Lower Extremity Wounds. INT J LOW EXTREM WOUNDS 7: 126-136 [Abstract]  
  • Yang, Q.-H., Botto, L. D, Gallagher, M., Friedman, J., Sanders, C. L, Koontz, D., Nikolova, S., Erickson, J D., Steinberg, K. (2008). Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am. J. Clin. Nutr. 88: 232-246 [Abstract] [Full text]  
  • Marini, N. J., Gin, J., Ziegle, J., Keho, K. H., Ginzinger, D., Gilbert, D. A., Rine, J. (2008). The prevalence of folate-remedial MTHFR enzyme variants in humans. Proc. Natl. Acad. Sci. USA 105: 8055-8060 [Abstract] [Full text]  
  • Myles, P. S., Chan, M. T. V., Leslie, K., Peyton, P., Paech, M., Forbes, A. (2008). Effect of nitrous oxide on plasma homocysteine and folate in patients undergoing major surgery. Br J Anaesth 100: 780-786 [Abstract] [Full text]  
  • Dangour, A. D., Breeze, E., Clarke, R., Shetty, P. S., Uauy, R., Fletcher, A. E. (2008). Plasma Homocysteine, but Not Folate or Vitamin B-12, Predicts Mortality in Older People in the United Kingdom. J. Nutr. 138: 1121-1128 [Abstract] [Full text]  
  • Chang, P.-Y., Lu, S.-C., Lee, C.-M., Chen, Y.-J., Dugan, T. A., Huang, W.-H., Chang, S.-F., Liao, W. S.L., Chen, C.-H., Lee, Y.-T. (2008). Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation. Circ. Res. 102: 933-941 [Abstract] [Full text]  
  • Larsson, S. C., Mannisto, S., Virtanen, M. J., Kontto, J., Albanes, D., Virtamo, J. (2008). Folate, Vitamin B6, Vitamin B12, and Methionine Intakes and Risk of Stroke Subtypes in Male Smokers. Am J Epidemiol 167: 954-961 [Abstract] [Full text]  
  • Bochud, M., Chiolero, A., Elston, R. C, Paccaud, F. (2008). A cautionary note on the use of Mendelian randomization to infer causation in observational epidemiology. Int J Epidemiol 37: 414-416 [Full text]  
  • Crowe, F. L., Skeaff, C. M., McMahon, J. A., Williams, S. M., Green, T. J. (2008). Lowering Plasma Homocysteine Concentrations of Older Men and Women with Folate, Vitamin B-12, and Vitamin B-6 Does Not Affect the Proportion of (n-3) Long Chain Polyunsaturated Fatty Acids in Plasma Phosphatidylcholine. J. Nutr. 138: 551-555 [Abstract] [Full text]  
  • Mann, J. F. E., Sheridan, P., McQueen, M. J., Held, C., Arnold, J. M. O., Fodor, G., Yusuf, S., Lonn, E. M., on behalf of the HOPE-2 investigators, (2008). Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant 23: 645-653 [Abstract] [Full text]  
  • Wagner, C., Koury, M. J (2007). S-Adenosylhomocysteine a better indicator of vascular disease than homocysteine?. Am. J. Clin. Nutr. 86: 1581-1585 [Abstract] [Full text]  
  • McCully, K. S (2007). Homocysteine, vitamins, and vascular disease prevention. Am. J. Clin. Nutr. 86: 1563S-1568S [Abstract] [Full text]  
  • Lazzerini, P.E., Capecchi, P.L., Selvi, E., Lorenzini, S., Bisogno, S., Galeazzi, M., Laghi Pasini, F. (2007). Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?. Lupus 16: 852-862 [Abstract]  
  • Glynn, R. J., Ridker, P. M, Goldhaber, S. Z., Buring, J. E. (2007). Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism: A Randomized Trial. ANN INTERN MED 147: 525-533 [Abstract] [Full text]  
  • Glynn, R. J., Ridker, P. M, Goldhaber, S. Z., Zee, R. Y.L., Buring, J. E. (2007). Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study. Circulation 116: 1497-1503 [Abstract] [Full text]  
  • Baigent, C., Clarke, R. (2007). B Vitamins for the Prevention of Vascular Disease: Insufficient Evidence to Justify Treatment. JAMA 298: 1212-1214 [Full text]  
  • de Bree, A., van Mierlo, L. A, Draijer, R. (2007). Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 86: 610-617 [Abstract] [Full text]  
  • Ludvigsson, J F, de Faire, U, Ekbom, A, Montgomery, S M (2007). Vascular disease in a population-based cohort of individuals hospitalised with coeliac disease. Heart 93: 1111-1115 [Abstract] [Full text]  
  • Siva, A., De Lange, M., Clayton, D., Monteith, S., Spector, T., Brown, M.J. (2007). The heritability of plasma homocysteine, and the influence of genetic variation in the homocysteine methylation pathway. QJM 100: 495-499 [Abstract] [Full text]  
  • Urquhart, B. L., Freeman, D. J., Spence, J. D., House, A. A. (2007). Mesna as a Nonvitamin Intervention to Lower Plasma Total Homocysteine Concentration: Implications for Assessment of the Homocysteine Theory of Atherosclerosis. J Clin Pharmacol 47: 991-997 [Abstract] [Full text]  
  • Agarwal, R. P., Peters, S. M., Shemirani, M., von Ahsen, N. (2007). Improved Real-Time Multiplex Polymerase Chain Reaction Detection of Methylenetetrahydrofolate Reductase (MTHFR) 677C>T and 1298A>C Polymorphisms Using Nearest Neighbor Model-Based Probe Design. J. Mol. Diagn. 9: 345-350 [Abstract] [Full text]  
  • Zittan, E., Preis, M., Asmir, I., Cassel, A., Lindenfeld, N., Alroy, S., Halon, D. A., Lewis, B. S., Shiran, A., Schliamser, J. E., Flugelman, M. Y. (2007). High frequency of vitamin B12 deficiency in asymptomatic individuals homozygous to MTHFR C677T mutation is associated with endothelial dysfunction and homocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 293: H860-H865 [Abstract] [Full text]  
  • Arnett, D. K., Baird, A. E., Barkley, R. A., Basson, C. T., Boerwinkle, E., Ganesh, S. K., Herrington, D. M., Hong, Y., Jaquish, C., McDermott, D. A., O'Donnell, C. J. (2007). Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115: 2878-2901 [Abstract] [Full text]  
  • Folstein, M., Liu, T., Peter, I., Buel, J., Arsenault, L., Scott, T., Qiu, W. W. (2007). The Homocysteine Hypothesis of Depression. Am. J. Psychiatry 164: 861-867 [Abstract] [Full text]  
  • Wierzbicki, A. S (2007). Homocysteine and cardiovascular disease: a review of the evidence. Diabetes and Vascular Disease Research 4: 143-149 [Abstract]  
  • Ueland, P. M., Clarke, R. (2007). Homocysteine and Cardiovascular Risk: Considering the Evidence in the Context of Study Design, Folate Fortification, and Statistical Power. Clin. Chem. 53: 807-809 [Full text]  
  • Zee, R. Y.L., Mora, S., Cheng, S., Erlich, H. A., Lindpaintner, K., Rifai, N., Buring, J. E., Ridker, P. M (2007). Homocysteine, 5,10-Methylenetetrahydrofolate Reductase 677C>T Polymorphism, Nutrient Intake, and Incident Cardiovascular Disease in 24 968 Initially Healthy Women. Clin. Chem. 53: 845-851 [Abstract] [Full text]  
  • Shirodaria, C., Antoniades, C., Lee, J., Jackson, C. E., Robson, M. D., Francis, J. M., Moat, S. J., Ratnatunga, C., Pillai, R., Refsum, H., Neubauer, S., Channon, K. M. (2007). Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid: Implications for Folate Therapy in Patients With Coronary Artery Disease. Circulation 115: 2262-2270 [Abstract] [Full text]  
  • Bezemer, I. D., Doggen, C. J. M., Vos, H. L., Rosendaal, F. R. (2007). No Association Between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results From the MEGA Study. Arch Intern Med 167: 497-501 [Abstract] [Full text]  
  • Venn, A., Britton, J. (2007). Exposure to Secondhand Smoke and Biomarkers of Cardiovascular Disease Risk in Never-Smoking Adults. Circulation 115: 990-995 [Abstract] [Full text]  
  • Haan, M. N, Miller, J. W, Aiello, A. E, Whitmer, R. A, Jagust, W. J, Mungas, D. M, Allen, L. H, Green, R. (2007). Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am. J. Clin. Nutr. 85: 511-517 [Abstract] [Full text]  
  • Hao, L., Ma, J., Zhu, J., Stampfer, M. J., Tian, Y., Willett, W. C., Li, Z. (2007). High Prevalence of Hyperhomocysteinemia in Chinese Adults Is Associated with Low Folate, Vitamin B-12, and Vitamin B-6 Status. J. Nutr. 137: 407-413 [Abstract] [Full text]  
  • Hajer, G. R, van der Graaf, Y., Olijhoek, J. K, Verhaar, M. C, Visseren, F. L J, for the SMART Study Group, (2007). Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart 93: 216-220 [Abstract] [Full text]  
  • Suliman, M., Stenvinkel, P., Qureshi, A. R., Kalantar-Zadeh, K., Barany, P., Heimburger, O., Vonesh, E. F., Lindholm, B. (2007). The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 22: 209-217 [Abstract] [Full text]  
  • den Heijer, M., Willems, H. P. J., Blom, H. J., Gerrits, W. B. J., Cattaneo, M., Eichinger, S., Rosendaal, F. R., Bos, G. M. J. (2007). Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109: 139-144 [Abstract] [Full text]  
  • Wald, D. S, Wald, N. J, Morris, J. K, Law, M. (2006). Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333: 1114-1117 [Full text]  
  • Bleys, J., Miller, E. R III, Pastor-Barriuso, R., Appel, L. J, Guallar, E. (2006). Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials.. Am. J. Clin. Nutr. 84: 880-887 [Abstract] [Full text]  
  • Pezzini, A, Grassi, M, Del Zotto, E, Assanelli, D, Archetti, S, Negrini, R, Caimi, L, Padovani, A (2006). Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis. J. Neurol. Neurosurg. Psychiatry 77: 1150-1156 [Abstract] [Full text]  
  • Dayal, S., Wilson, K. M., Leo, L., Arning, E., Bottiglieri, T., Lentz, S. R. (2006). Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 108: 2237-2243 [Abstract] [Full text]  
  • Soumare, A., Elbaz, A., Ducros, V., Tavernier, B., Alperovitch, A., Tzourio, C. (2006). Cross-sectional association between homocysteine and motor function in the elderly.. Neurology 67: 985-990 [Abstract] [Full text]  
  • Antoniades, C., Shirodaria, C., Warrick, N., Cai, S., de Bono, J., Lee, J., Leeson, P., Neubauer, S., Ratnatunga, C., Pillai, R., Refsum, H., Channon, K. M. (2006). 5-Methyltetrahydrofolate Rapidly Improves Endothelial Function and Decreases Superoxide Production in Human Vessels: Effects on Vascular Tetrahydrobiopterin Availability and Endothelial Nitric Oxide Synthase Coupling. Circulation 114: 1193-1201 [Abstract] [Full text]  
  • Kaul, S., Zadeh, A. A., Shah, P. K. (2006). Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not Validated. J Am Coll Cardiol 48: 914-923 [Abstract] [Full text]  
  • Shenkin, A (2006). Micronutrients in health and disease.. Postgrad. Med. J. 82: 559-567 [Abstract] [Full text]  
  • Casas, J. P, Shah, T., Cooper, J., Hawe, E., McMahon, A. D, Gaffney, D., Packard, C. J, O'Reilly, D. S, Juhan-Vague, I., Yudkin, J. S, Tremoli, E., Margaglione, M., Di Minno, G., Hamsten, A., Kooistra, T., Stephens, J. W, Hurel, S. J, Livingstone, S., Colhoun, H. M, Miller, G. J, Bautista, L. E, Meade, T., Sattar, N., Humphries, S. E, Hingorani, A. D (2006). Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35: 922-931 [Abstract] [Full text]  
  • Mittleman, M. A. (2006). A 39-year-old woman with hypercholesterolemia.. JAMA 296: 319-326 [Abstract] [Full text]  
  • de Craen, A. J.M., Stott, D. J., Westendorp, R. G.J., Khare, A., Lopez, M., Gogtay, J., Quinlivan, E. P., Gregory, J. F. III, Refsum, H., Smith, A. D., Wang, X., Demirtas, H., Xu, X., Tomlinson, D. R., Lang, D., Lewis, M. J., Lonn, E., the HOPE-2 Investigators, , Bonaa, K. H., Tverdal, A., Ueland, P. M. (2006). Homocysteine, B vitamins, and cardiovascular disease.. NEJM 355: 205-206 [Full text]  
  • Sleight, P., Pouleur, H., Zannad, F. (2006). Benefits, challenges, and registerability of the polypill. Eur Heart J 27: 1651-1656 [Abstract] [Full text]  
  • McKillop, D. J, McNulty, H., Scott, J. M, McPartlin, J. M, Strain, J., Bradbury, I., Girvan, J., Hoey, L., McCreedy, R., Alexander, J., Patterson, B K., Hannon-Fletcher, M., Pentieva, K. (2006). The rate of intestinal absorption of natural food folates is not related to the extent of folate conjugation. Am. J. Clin. Nutr. 84: 167-173 [Abstract] [Full text]  
  • MacKenzie, K. E., Wiltshire, E. J., Gent, R., Hirte, C., Piotto, L., Couper, J. J. (2006). Folate and Vitamin B6 Rapidly Normalize Endothelial Dysfunction In Children With Type 1 Diabetes Mellitus. Pediatrics 118: 242-253 [Abstract] [Full text]  
  • Holven, K. B., Halvorsen, B., Bjerkeli, V., Damas, J. K., Retterstol, K., Morkrid, L., Ose, L., Aukrust, P., Nenseter, M. S. (2006). Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects. Stroke 37: 1731-1736 [Abstract] [Full text]  
  • Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e873-e923 [Abstract] [Full text]  
  • Nettleton, J. A, Steffen, L. M, Mayer-Davis, E. J, Jenny, N. S, Jiang, R., Herrington, D. M, Jacobs, D. R Jr (2006). Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Clin. Nutr. 83: 1369-1379 [Abstract] [Full text]  
  • Lutsey, P. L, Steffen, L. M, Feldman, H. A, Hoelscher, D. H, Webber, L. S, Luepker, R. V, Lytle, L. A, Zive, M., Osganian, S. K (2006). Serum homocysteine is related to food intake in adolescents: the Child and Adolescent Trial for Cardiovascular Health. Am. J. Clin. Nutr. 83: 1380-1386 [Abstract] [Full text]  
  • Undas, A., Brozek, J., Jankowski, M., Siudak, Z., Szczeklik, A., Jakubowski, H. (2006). Plasma Homocysteine Affects Fibrin Clot Permeability and Resistance to Lysis in Human Subjects. Arterioscler. Thromb. Vasc. Bio. 26: 1397-1404 [Abstract] [Full text]  
  • Refsum, H., Nurk, E., Smith, A. D., Ueland, P. M., Gjesdal, C. G., Bjelland, I., Tverdal, A., Tell, G. S., Nygard, O., Vollset, S. E. (2006). The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease. J. Nutr. 136: 1731S-1740S [Abstract] [Full text]  
  • Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 1583-1633 [Abstract] [Full text]  
  • Vasan, R. S. (2006). Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. Circulation 113: 2335-2362 [Full text]  
  • Loscalzo, J. (2006). Homocysteine Trials -- Clear Outcomes for Complex Reasons. NEJM 354: 1629-1632 [Full text]  
  • Bonaa, K. H., Njolstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., Rasmussen, K., the NORVIT Trial Investigators, (2006). Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. NEJM 354: 1578-1588 [Abstract] [Full text]  
  • The Heart Outcomes Prevention Evaluation (HOPE) 2, (2006). Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. NEJM 354: 1567-1577 [Abstract] [Full text]  
  • Menon, V., Sarnak, M. J., Greene, T., Wang, X., Pereira, A. A., Beck, G. J., Kusek, J. W., Selhub, J., Collins, A. J., Levey, A. S., Shlipak, M. G. (2006). Relationship Between Homocysteine and Mortality in Chronic Kidney Disease. Circulation 113: 1572-1577 [Abstract] [Full text]  
  • Wuerges, J., Garau, G., Geremia, S., Fedosov, S. N., Petersen, T. E., Randaccio, L. (2006). Structural basis for mammalian vitamin B12 transport by transcobalamin. Proc. Natl. Acad. Sci. USA 103: 4386-4391 [Abstract] [Full text]  
  • Yang, Q., Botto, L. D., Erickson, J. D., Berry, R. J., Sambell, C., Johansen, H., Friedman, J.M. (2006). Improvement in Stroke Mortality in Canada and the United States, 1990 to 2002. Circulation 113: 1335-1343 [Abstract] [Full text]  
  • Devlin, A. M., Lentz, S. R. (2006). ApoA-I: A Missing Link Between Homocysteine and Lipid Metabolism?. Circ. Res. 98: 431-433 [Full text]  
  • Devlin, A. M, Clarke, R., Birks, J., Evans, J. G., Halsted, C. H (2006). Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am. J. Clin. Nutr. 83: 708-713 [Abstract] [Full text]  
  • Lee, K. W.J., Hill, J. S., Walley, K. R., Frohlich, J. J. (2006). Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort.. CMAJ 174: 461-466 [Abstract] [Full text]  
  • Ho, G. Y.-H., Eikelboom, J. W., Hankey, G. J., Wong, C.-R., Tan, S.-L., Chan, J. B.-C., Chen, C. P.L.-H. (2006). Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients. Stroke 37: 456-460 [Abstract] [Full text]  
  • Kamath, A. F., Chauhan, A. K., Kisucka, J., Dole, V. S., Loscalzo, J., Handy, D. E., Wagner, D. D. (2006). Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 107: 591-593 [Abstract] [Full text]  
  • McNulty, H., Dowey, L. R. C., Strain, J.J., Dunne, A., Ward, M., Molloy, A. M., McAnena, L. B., Hughes, J. P., Hannon-Fletcher, M., Scott, J. M. (2006). Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C->T Polymorphism. Circulation 113: 74-80 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

MTHFR C677T not valuable thrombophilia test
Joel G Ray
bmj.com, 22 Nov 2002 [Full text]
Diet-induced Folate Deficiency
Bill D. Misner
bmj.com, 23 Nov 2002 [Full text]
Another cardiovascular effect of homocysteine
Serdar KULA
bmj.com, 23 Nov 2002 [Full text]
Minimising the risk of deep venous thrombosis through genetic screening
Maritha J Kotze, et al.
bmj.com, 26 Nov 2002 [Full text]
Homocysteine causes mitochondrial dysfunction
Richard G Fiddian-Green, et al.
bmj.com, 3 Dec 2002 [Full text]
Observational data do not prove homocysteine is causal in cardiovascular disease
Sagar N Doshi, et al.
bmj.com, 6 Dec 2002 [Full text]
Meta-analysis of homocyst(e)ine in CVD
Dan G. Hackam
bmj.com, 15 Dec 2002 [Full text]
Do port and red wine preserve ATP stores?
Richard G Fiddian-Green
bmj.com, 16 Dec 2002 [Full text]
Homocysteine, ATP degradation and free radical release.
Richard G Fiddian-Green
bmj.com, 18 Dec 2002 [Full text]
Homocysteine, folic acid, uric acid, ATP and free radical scavenging
Richard G Fiddian-Green
bmj.com, 19 Dec 2002 [Full text]
Exercise and plasma homocysteine
Harpal S Randeva, et al.
bmj.com, 20 Dec 2002 [Full text]
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
Miranda B. Keijzer, et al.
bmj.com, 20 Dec 2002 [Full text]
Testing travellers for MTHFR TT is absurd
Joel G Ray
bmj.com, 22 Dec 2002 [Full text]
Pre-travel screening to identify genetic factors predisposing to thrombosis
Maritha J Kotze
bmj.com, 27 Dec 2002 [Full text]
Re: pre-travel screening for thromboembolism
Richard G Fiddian-Green
bmj.com, 30 Dec 2002 [Full text]
Re: Pre-travel screening may be harmful
Joel G Ray
bmj.com, 30 Dec 2002 [Full text]
"Lactic acidosis": the common denominator?
Richard G Fiddian-Green
bmj.com, 3 Jan 2003 [Full text]
Pre-test assessment to determine appropriateness of pre-travel genetic screening for thrombosis risk
Maritha J Kotze
bmj.com, 4 Jan 2003 [Full text]
Role of renal impairment.
Dan Hackam
bmj.com, 7 Jan 2003 [Full text]
Role of renal impairment.
Dan Hackam
bmj.com, 5 Jan 2003 [Full text]
Homocysteine: an adenine nucleotide trap?
Richard G Fiddian-Green
bmj.com, 9 Jan 2003 [Full text]
pH/calcium regulation of homocysteine metabolism
Richard G Fiddian-Green
bmj.com, 10 Jan 2003 [Full text]
Biochemical definitions
Richard G Fiddian-Green
bmj.com, 10 Jan 2003 [Full text]
MTHFR gene mutation, methylmalonic acidosis, and exercise.
Richard G Fiddian-Green
bmj.com, 19 Jan 2003 [Full text]
MTHFR and meta-Analysis
Markus Weih
bmj.com, 16 Jan 2003 [Full text]
The MTHFR poymorphism and screening for deep vein thrombosis
David S Wald, et al.
bmj.com, 31 Jan 2003 [Full text]
Re: Observational data do not prove homocysteine is causal in cardiovascular disease
David S Wald, et al.
bmj.com, 31 Jan 2003 [Full text]
Re: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
David S Wald, et al.
bmj.com, 31 Jan 2003 [Full text]
Genetic equilibrium suggests no link between MTHFR and ischaemic heart disease.
Gavin Willis, et al.
bmj.com, 7 Apr 2003 [Full text]
Doc2Doc Vacancy
Access jobs at BMJ Careers
Whats new online at Student BMJ